National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report.
暂无分享,去创建一个
M. Mohty | Stephanie J. Lee | S. Pavletic | C. Cutler | G. Akpek | G. Vogelsang | D. Wolff | D. Przepiorka | P. Carpenter | J. Koreth | I. Walker | L. Griffith | M. Horowitz | P. Martin | Linda M. Griffith
[1] Anita Lawitschka,et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[2] Daniel Wolff,et al. Measuring Therapeutic Response in Chronic Graft-versus-host-disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus- Host Disease: Iv. Response Criteria Working Group Report , 2022 .
[3] D. Miklos,et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[4] K. Washington,et al. NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[5] H. Greinix,et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease , 2015 .
[6] Paul J Martin,et al. How we treat chronic graft-versus-host disease. , 2015, Blood.
[7] T. Panzarella,et al. Thymoglobulin Decreases the Need for Immunosuppression at 12 Months after Myeloablative and Nonmyeloablative Unrelated Donor Transplantation: CBMTG 0801, a Randomized, Controlled Trial , 2014 .
[8] Ö. Bostan,et al. The Role of Cardiovascular T2*MRI and Tissue Doppler Measurement in Assesment of Cardiac Status in β-Thalassemia Major , 2014 .
[9] S. Steinberg,et al. NIH response criteria measures are associated with important parameters of disease severity in patients with chronic GVHD , 2014, Bone Marrow Transplantation.
[10] B. Storer,et al. Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease , 2014, Haematologica.
[11] P. Tugwell,et al. Toward a Generalized Framework of Core Measurement Areas in Clinical Trials: A Position Paper for OMERACT 11 , 2014, The Journal of Rheumatology.
[12] P. Tugwell,et al. Updating the OMERACT Filter at OMERACT 11 , 2014, The Journal of Rheumatology.
[13] J. Goldberg,et al. Assessment of Joint and Fascia Manifestations in Chronic Graft‐Versus‐Host Disease , 2014, Arthritis & rheumatology.
[14] W. Wood,et al. Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[15] Khaled Bouri,et al. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012. , 2014, JAMA.
[16] Harlan M. Krumholz,et al. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. , 2014, JAMA.
[17] S. Goodman,et al. Opening the FDA black box. , 2014, JAMA.
[18] S. Svegliati,et al. Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD. , 2013, Blood.
[19] B. Kurland,et al. Measurement of oral chronic GVHD: results from the Chronic GVHD Consortium , 2013, Bone Marrow Transplantation.
[20] B. Sandmaier,et al. Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease. , 2013, Blood.
[21] B. Storer,et al. Poor agreement between clinician response ratings and calculated response measures in patients with chronic graft-versus-host disease. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[22] B. Storer,et al. Clinical benefit of response in chronic graft-versus-host disease. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[23] B. Kurland,et al. Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. , 2012, Blood.
[24] T. Braun,et al. Soluble tumor necrosis factor receptor: enbrel (etanercept) for subacute pulmonary dysfunction following allogeneic stem cell transplantation. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[25] B. Kurland,et al. Validation of measurement scales in ocular graft-versus-host disease. , 2012, Ophthalmology.
[26] J. Bijlsma,et al. The Systemic Lupus Erythematosus Responder Index (SRI); a new SLE disease activity assessment. , 2012, Autoimmunity reviews.
[27] D. Parenti,et al. Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis--results of a crossover randomized study. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[28] M. Petri,et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. , 2011, Arthritis and rheumatism.
[29] Li Li,et al. A multicenter pilot evaluation of the National Institutes of Health chronic graft-versus-host disease (cGVHD) therapeutic response measures: feasibility, interrater reliability, and minimum detectable change. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[30] B. Storer,et al. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. , 2011, Blood.
[31] B. Kurland,et al. Sensitivity of changes in chronic graft-versus-host disease activity to changes in patient-reported quality of life: results from the Chronic Graft-versus-Host Disease Consortium , 2011, Haematologica.
[32] J. Perkins,et al. Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids , 2011, Haematologica.
[33] Stephanie J. Lee,et al. Treatment of chronic graft-versus-host disease: Past, present and future , 2011, The Korean journal of hematology.
[34] B. Kurland,et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. , 2011, Blood.
[35] R. Storb,et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. , 2011, Blood.
[36] David T Felson,et al. UvA-DARE (Digital Academic Repository) American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials , 2011 .
[37] E. Holler,et al. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[38] C. Cleeland,et al. A New Measure Of Symptom Burden In Chronic Graft-Versus-Host Disease , 2010 .
[39] A. Rademaker,et al. Skin response using NIH consensus criteria vs Hopkins scale in a phase II study for steroid-refractory chronic GVHD , 2009, Bone Marrow Transplantation.
[40] B. Storer,et al. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. , 2009, Blood.
[41] B. Storer,et al. Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[42] L. Bouzas,et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. , 2008, Blood.
[43] Philippe Marteau,et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. , 2007, Gastroenterology.
[44] R. Soiffer,et al. Quality of life associated with acute and chronic graft-versus-host disease , 2006, Bone Marrow Transplantation.
[45] S. Hirschfeld,et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[46] Daniel Wolff,et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[47] E. Cook,et al. Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[48] H. Deeg,et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. , 2002, Blood.
[49] D. Gladman,et al. Systemic lupus erythematosus disease activity index 2000. , 2002, The Journal of rheumatology.
[50] P. Rutgeerts,et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. , 2002, Gastroenterology.
[51] J J Anderson,et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. , 2001, Arthritis and rheumatism.
[52] S. Davies,et al. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[53] B. Craven,et al. Quality of life and psychological distress of bone marrow transplant recipients: the ‘time trajectory’ to recovery over the first year , 1998, Bone Marrow Transplantation.
[54] A. Bonomi,et al. Quality of life measurement in bone marrow transplantation: development of the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) scale , 1997, Bone Marrow Transplantation.
[55] J J Anderson,et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. , 1995, Arthritis and rheumatism.
[56] D A Isenberg,et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. , 1993, The Quarterly journal of medicine.
[57] E. Schned,et al. Derivation of the SLEDAI. , 1993, Arthritis and rheumatism.
[58] D. Sackett,et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. , 1992, Arthritis and rheumatism.
[59] M. Liang,et al. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. , 1989, Arthritis and rheumatism.
[60] Jean E. Sanders,et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. , 1988, Blood.
[61] K. Sullivan,et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. , 1981, Blood.
[62] A. Claudy,et al. Disease activity in systemic lupus erythematosus , 1979, Clinical and experimental dermatology.
[63] F Kern,et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. , 1976, Gastroenterology.
[64] B. Sandmaier,et al. Failure-free survival after initial systemic treatment of chronic graft-versus-host disease. , 2014, Blood.
[65] S. Steinberg,et al. Validation of the National Institutes of Health chronic GVHD Oral Mucosal Score using component-specific measures , 2014, Bone Marrow Transplantation.
[66] M. Pasquini,et al. 2013 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. , 2013, Clinical transplants.
[67] S. Grupp,et al. Randomized trial of hydroxychloroquine for newly diagnosed chronic graft-versus-host disease in children: a Children's Oncology Group study. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[68] M. Mohty,et al. Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[69] B. Storer,et al. Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[70] R. Arceci. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease , 2009 .
[71] P. Lachenbruch,et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[72] J. Ware. SF-36 health survey: Manual and interpretation guide , 2003 .
[73] H. Deeg,et al. Thalidomide for treatment of patients with chronic graft-versus-host disease. , 2000, Blood.
[74] John E. Ware,et al. SF-36 physical and mental health summary scales : a user's manual , 1994 .